Previous 10 | Next 10 |
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced upcoming presentations inc...
2023-04-03 16:41:21 ET Summary Merger arbitrage spreads are wide. There are plenty of opportunities with spreads of up to 118%. This is a review of the most interesting transactions in the merger arbitrage space. Merger arbitrage is an event-driven investment strategy of...
2023-03-28 16:48:35 ET Infinity Pharmaceuticals press release ( NASDAQ: INFI ): FY GAAP EPS of -$0.50 misses by $0.11 . Revenue of $2.59M (+39.2% Y/Y) misses by $11.31M . At December 31, 2022, Infinity had total cash and cash equivalents of $38.3 million, compa...
– Infinity ended 2022 with total cash and cash equivalents of $38.3 million – – Infinity Previously Announced Definitive Merger Agreement with MEI Pharma to Advance Three Promising Clinical Oncology Candidates – Infinity Pharmaceuticals, Inc. (NASDAQ:...
VANCOUVER, BC / ACCESSWIRE / March 15, 2023 / Infinitum Copper Corp. (TSXV:INFI)(OTCQB:INUMF) (" Infinitum " or the " Company ") is pleased to announce a private placement to raise gross proceeds of up to C$1,500,000 through the issue of up to 21,428,571 units of the Company (the " Units ") at a...
NEW YORK, NY / ACCESSWIRE / March 5, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: INDUS Realty Trust, Inc. (NASDAQ: IND...
NEW YORK, NY / ACCESSWIRE / February 26, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Jounce Therapeutics, Inc. (NAS...
Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M cash balance of combined company expected to fund operations through...
VANCOUVER, BC / ACCESSWIRE / February 22, 2023 / Infinitum Copper Corp. (TSXV:INFI)(OTCQB:INUMF) (" Infinitum " or the " Company ") is pleased to announce the successful closing of the previously announced transaction with Prismo Metals Inc. (CSE: PRIZ, OTCQB: PMOMF) ("Prismo") with respect to H...
VANCOUVER, BC / ACCESSWIRE / February 9, 2023 / Infinitum Copper Corp. (TSXV:INFI)(OTCQB:INUMF) (" Infinitum " or the " Company ") announces that Matt Hudson has been appointed as President and CEO of the Company effective February 1, 2023. Matt's operational experience in Mexico, knowledge of c...
News, Short Squeeze, Breakout and More Instantly...
Infinity Pharmaceuticals Inc. Company Name:
INFI Stock Symbol:
NASDAQ Market:
Infinity Pharmaceuticals Inc. Website:
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - Infinitum Copper Corp. (TSXV: INFI) (OTCQB: INUMF) (" Infinitum " or the " Company ") is pleased to announce that it has received acceptance from the TSX Venture Exchange (the " Exchange ") of the previously announced consolidation ...
VANCOUVER, BC / ACCESSWIRE / April 3, 2024 / Infinitum Copper Corp. (TSXV:INFI, OTCQB:INUMF) (" Infinitum " or the " Company ") is pleased to announce the details of a proposed consolidation of its common shares. On March 21, 2024, in accordance with the constating documents of the Company, the ...
VANCOUVER, BC / ACCESSWIRE / March 6, 2024 / Infinitum Copper Corp. (TSXV:INFI)(OTCQB:INUMF) (" Infinitum " or the " Company "). Further to the Company's news release of March 5, 2024 (the " March 5, 2024 News Release "), this is to advise that the Company has amended the terms of its private pl...